Physician profile
Mary Reed
NPI 1043393523
$1,669.04
in general payments reported to CMS, 2019-2025
25 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $271 · 2021: $11.92 · 2022: $288 · 2023: $138 · 2024: $135 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $232.32 | 2019-2020 | |
| Janssen Biotech, INC. | $198.90 | 2020-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $190.70 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $122.12 | 2020-2024 | Xtandi |
| Lilly USA, LLC | $92.91 | 2019 | |
| Celgene Corporation | $91.57 | 2022-2023 | Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $86.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.60 | 2020-2025 | Opdivo |
| Incyte Corporation | $81.42 | 2019-2025 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $55.26 | 2023 | Imbruvica |
| Abbvie INC. | $50.62 | 2025 | |
| Janssen Scientific Affairs, LLC | $43.80 | 2019 | |
| Pfizer INC. | $40.21 | 2019 | |
| Gilead Sciences, INC. | $38.96 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $38.33 | 2025 | Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.80 | 2022 | |
| Taiho Oncology, INC. | $25.49 | 2022 | |
| Puma Biotechnology, INC. | $24.78 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.63 | 2025 | Qinlock, Romvimza |
| Janssen Pharmaceuticals, INC | $22.57 | 2022 | |
| Genzyme Corporation | $20.50 | 2025 | |
| Merck Sharp & Dohme LLC | $20.50 | 2022 | |
| Amgen INC. | $20.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.14 | 2019 | |
| Tesaro, INC. | $17.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.